NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) has been added to the Russell Microcap Index, effective when the US market opens on June 29, as part of the 2026 Russell indexes reconstitution. The announcement, made by the company on June 29, 2026, marks a significant milestone for the medical technology firm, which focuses on transforming the surgical diagnosis and treatment of neurological disorders.
The inclusion in the Russell Microcap Index, which consists of the smallest 1,000 securities in the Russell 2000 Index plus the next 1,000 smallest eligible securities by market cap, is based on objective market-capitalization rankings and style attributes determined by FTSE Russell. The semi-annual June reconstitution of the Russell US Indexes captures the 4,000 largest US stocks as of April 30, ranking them by total market capitalization. Membership in the Russell 3000 Index, which remains in place for half a year beginning 2026, implies automatic inclusion in the large-cap Russell 1000 Index or small-cap Russell 2000 Index, as well as the appropriate growth and value style indexes.
The Russell indexes are widely used by investment managers and institutional investors for index funds and as benchmarks for active investment strategies. As of the end of June 2025, approximately $12.2 trillion in assets were benchmarked against the Russell US indexes, which belong to FTSE Russell, the global index provider. For more information on the Russell Microcap Index and the reconstitution, visit the FTSE Russell website.
NeuroOne markets a minimally invasive and high-definition/high-precision electrode technology platform with four FDA-cleared product families: Evo Cortical Electrodes, Evo sEEG Electrodes, OneRF Ablation System (for brain), and OneRF Trigeminal Nerve Ablation System. These solutions offer the potential to reduce the number of hospitalizations and surgical procedures, lower costs, and improve patient outcomes by providing diagnostic and therapeutic functions. The company is also engaged in research and development for drug delivery, basivertebral nerve ablation, and spinal cord stimulation programs. For more information, visit nmtc1.com.
The addition to the Russell Microcap Index is expected to increase NeuroOne's visibility among institutional investors and could lead to greater liquidity and demand for its stock as index funds adjust their holdings. This development underscores the company's growing presence in the medical technology sector and its potential for future growth.
